Plasma Fractionation Market: Plasma Collection Centers, Processing & Market Outlook

Posté 2026-09-11 05:11:19

Plasma Fractionation Market: Growth, Trends, Demand & Forecast to 2033

Plasma Fractionation Market Overview

The global Plasma Fractionation Market is witnessing steady expansion as demand for plasma-derived therapies continues to increase across healthcare systems. The market was valued at approximately USD 34.4 billion in 2025 and is projected to reach USD 55.3 billion by 2033, growing at a CAGR of 6.4% during the forecast period.

Plasma fractionation is an industrial process used to separate plasma into valuable protein components that can be further processed into therapeutic products. These products include immunoglobulins, albumin, coagulation factors, and other plasma-derived medicinal products used in the management of various medical conditions. The European Medicines Agency recognizes albumin, coagulation factors, and immunoglobulins among the major plasma-derived medicinal products.

The growing prevalence and awareness of rare and chronic diseases, increasing use of immunoglobulin therapies, improvements in healthcare infrastructure, and greater attention to plasma collection are supporting market development.

According to M2Square Consultancy, the Plasma Fractionation Market is expected to benefit from increasing demand for plasma-derived therapies, investments in plasma collection infrastructure, advancements in fractionation technologies, and efforts to strengthen the global supply of essential plasma-derived medicinal products.

Key Market Highlights

2025 Market Size: USD 34.4 Billion
2033 Market Forecast: USD 55.3 Billion
CAGR: 6.4%
Forecast Period: 2025–2033
Major Growth Factor: Rising demand for plasma-derived therapies
Key Products: Immunoglobulins, albumin, coagulation factors and other plasma-derived products
Major Opportunities: Plasma collection expansion, fractionation capacity, emerging economies and advanced processing technologies

View the Full Plasma Fractionation Market Research Report:https://m2squareconsultancy.com/reports/plasma-fractionation-market

Explore detailed insights covering market size, growth trends, product segmentation, regional analysis, competitive landscape, demand drivers, industry developments, emerging technologies, and future opportunities in the Plasma Fractionation Market.

What Is Plasma Fractionation?

Plasma fractionation is the process of separating human blood plasma into individual proteins and other components that can be purified and manufactured into therapeutic products.

The process generally involves several stages, including:

Plasma collection
Plasma testing and screening
Pooling
Protein separation
Purification
Viral inactivation and removal
Formulation
Filling and packaging
Quality testing

The resulting plasma-derived products can be used for conditions involving immune deficiencies, bleeding disorders, protein deficiencies, and other serious diseases.

Because these products are derived from human plasma, maintaining strict quality and safety controls throughout collection and manufacturing is essential. EMA requirements include controls related to plasma quality, manufacturing consistency, and the demonstration of appropriate viral safety.

Key Factors Driving Plasma Fractionation Market Growth

Rising Demand for Plasma-Derived Therapies

One of the most important growth factors is increasing demand for plasma-derived medicinal products.

Immunoglobulins are used in the treatment and management of several immune-related conditions, while coagulation factors support the treatment of bleeding disorders. Albumin is also an important plasma-derived therapeutic product.

The WHO identifies immunoglobulins and coagulation factors as medically important plasma-derived medicinal products and highlights the need for sufficient and equitable supply globally.

Growing Prevalence of Rare and Chronic Diseases

The diagnosis and treatment of rare diseases, immune disorders, bleeding disorders, and other chronic conditions are expanding the patient population requiring specialized therapies.

Greater disease awareness and improvements in diagnosis are also enabling more patients to receive appropriate treatment, supporting long-term demand for plasma-derived products.

Expansion of Plasma Collection Infrastructure

The availability of suitable plasma is fundamental to the fractionation industry.

Investments in plasma collection centers, donor recruitment, testing infrastructure, and plasma management systems can increase the supply of raw material available for fractionation.

WHO data show that plasma collection and domestic fractionation capacity remain uneven globally, creating opportunities to strengthen national and regional plasma programs.

Healthcare Infrastructure Development

Developing healthcare systems are increasingly investing in specialized diagnostics, hospitals, biotechnology infrastructure, and advanced therapies.

As access to healthcare improves, the use of plasma-derived medicines can expand across emerging markets.

Increasing Focus on Supply Security

Plasma-derived medicinal products are strategically important for healthcare systems. Supply disruptions can affect patients who depend on these therapies.

Governments and healthcare organizations are therefore placing greater emphasis on sustainable plasma collection, domestic or regional processing capacity, and diversified supply networks. WHO's recent guidance also addresses cross-border transfer of domestic plasma for foreign fractionation as one approach to improving availability and affordability.

Emerging Trends in the Plasma Fractionation Market

Growing Use of Immunoglobulin Therapies

Immunoglobulins remain an important category within plasma-derived therapies. Continued demand from immunodeficiency and other clinical applications is supporting investments across plasma collection and fractionation.

Expansion of Plasma Collection Centers

Plasma collection infrastructure is expanding as manufacturers and healthcare systems seek to increase the availability of source plasma.

Improved donor recruitment, collection technologies, testing procedures, and donor-management systems are becoming increasingly important.

Advanced Purification and Fractionation Technologies

Manufacturers are investing in improved separation, purification, filtration, and viral-inactivation technologies.

These advancements aim to improve product quality, manufacturing efficiency, yield, and safety.

Increased Focus on Viral Safety

Because plasma-derived products originate from human plasma, safety and pathogen control remain critical.

Regulatory frameworks require manufacturers to apply appropriate controls and demonstrate viral safety. EMA guidance specifically addresses transmissible-agent considerations for plasma-derived medicinal products.

Regionalization of Plasma Supply

Countries and healthcare systems are increasingly evaluating ways to improve domestic or regional access to plasma-derived products.

This includes developing national plasma programs, strengthening collection infrastructure, and establishing arrangements for contract or toll fractionation.

Digitalization of Plasma Operations

Digital technologies are increasingly being used for donor management, plasma inventory monitoring, quality tracking, manufacturing analytics, and supply-chain visibility.

These systems can help organizations improve operational efficiency and manage complex plasma supply networks.

Plasma Fractionation Market Segmentation

By Product

Albumin
Immunoglobulins
Coagulation Factor Concentrates
Alpha-1 Antitrypsin
Other Plasma-Derived Products

By Fractionation Process

Cohn Fractionation
Chromatography
Combination Processes
Other Advanced Fractionation Technologies

By Application

Immunodeficiency Disorders
Hemophilia
Primary Immunodeficiency
Secondary Immunodeficiency
Liver Diseases
Neurological Disorders
Other Medical Conditions

By End User

Hospitals
Specialty Clinics
Pharmaceutical Companies
Blood and Plasma Centers
Research Institutions
Other Healthcare Facilities

Regional Outlook

North America

North America represents a major market for plasma fractionation due to its established plasma collection infrastructure, advanced healthcare system, strong pharmaceutical industry, and high demand for plasma-derived therapies.

The region is expected to remain an important center for plasma collection, fractionation, research, and manufacturing.

Europe

Europe has a well-developed regulatory and healthcare environment supporting the safe production and use of plasma-derived medicinal products.

The region is also focusing on improving the resilience and sustainability of blood and plasma systems while maintaining stringent quality standards.

Asia Pacific

Asia Pacific is expected to offer significant growth opportunities due to improving healthcare infrastructure, increasing awareness of rare and chronic diseases, expanding pharmaceutical manufacturing capabilities, and rising healthcare expenditure.

The region also presents opportunities to strengthen domestic plasma collection and fractionation capabilities.

Latin America

Latin American countries are gradually improving healthcare infrastructure and access to specialized therapies. Growth in plasma collection programs and pharmaceutical capabilities can create additional opportunities for the market.

Middle East & Africa

The Middle East and Africa represent emerging opportunities as healthcare systems develop and governments seek improved access to essential blood and plasma-derived products.

Limited local plasma collection and fractionation capacity in several countries also creates opportunities for infrastructure investment and regional partnerships.

Competitive Landscape

The global Plasma Fractionation Market includes specialized plasma-product manufacturers, biopharmaceutical companies, and organizations involved in plasma collection and processing.

Key players include:

CSL Limited
Grifols S.A.
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A.
Bio Products Laboratory
China Biologic Products Holdings
LFB S.A.
ADMA Biologics
GC Biopharma
Sanquin
SK Plasma

Companies are focusing on expanding plasma collection networks, increasing fractionation capacity, developing plasma-derived therapies, improving manufacturing efficiency, and strengthening global supply capabilities.

Key Challenges in the Plasma Fractionation Market

Limited Plasma Availability

Plasma is the essential raw material for plasma-derived products. Insufficient collection can constrain manufacturing capacity and contribute to supply shortages.

High Manufacturing Costs

Plasma fractionation requires specialized facilities, advanced processing equipment, extensive testing, and strict quality-control systems.

Regulatory Requirements

Plasma-derived medicinal products are subject to stringent quality, safety, manufacturing, and traceability requirements. These requirements can increase development and manufacturing complexity.

Complex Supply Chains

The industry depends on coordinated plasma collection, transportation, testing, storage, fractionation, manufacturing, and distribution.

Any disruption at one stage can affect product availability.

Long Manufacturing Cycles

Plasma-derived products require multiple processing and quality-control stages. This can make supply expansion more complex compared with some synthetic pharmaceutical products.

Uneven Global Access

Access to plasma-derived medicinal products varies significantly between countries. WHO reports that many countries rely on imported products or do not have domestic plasma fractionation capacity.

Future Outlook

The future of the Plasma Fractionation Market will be shaped by the growing medical importance of plasma-derived therapies and the need for a more secure and sustainable plasma supply.

Manufacturers are expected to continue investing in plasma collection centers, fractionation facilities, purification technologies, quality systems, and supply-chain capabilities.

Emerging economies may provide significant opportunities as healthcare infrastructure improves and countries seek to increase access to essential plasma-derived medicines. WHO continues to emphasize sustainable blood and plasma programs and improved access to plasma-derived medicinal products.

The market is projected to increase from USD 34.4 billion in 2025 to USD 55.3 billion by 2033, registering a CAGR of 6.4%. This growth reflects the increasing clinical importance of plasma-derived therapies, improvements in healthcare infrastructure, and continued investment in plasma collection and fractionation capabilities.

Frequently Asked Questions

What is the Plasma Fractionation Market?

What is plasma fractionation used for?

What are the major products derived from plasma fractionation?

What is driving the growth of the Plasma Fractionation Market?

Why is plasma collection important for the fractionation industry?

What role do immunoglobulins play in the Plasma Fractionation Market?

Which regions are expected to offer growth opportunities in the Plasma Fractionation Market?

What are the major challenges facing the plasma fractionation industry?

About M2Square Consultancy

At M2Square Consultancy, we don’t just study markets — we decode them.

Founded in 2023, M2Square Consultancy is a market research and business intelligence firm providing data-driven insights across healthcare, biotechnology, pharmaceuticals, ICT, energy, chemicals, consumer goods, automotive, and other high-growth industries.

Our services include syndicated research, custom research, competitive intelligence, customer insights, market sizing, trend analysis, pricing strategy, and go-to-market consulting.

Author

Written by Shubham
Senior Healthcare & Biotechnology Market Research Analyst | M2Square Consultancy

Shubham specializes in pharmaceuticals, biotechnology, healthcare, life sciences, plasma-derived therapies, and medical technologies, focusing on market intelligence, healthcare trends, competitive analysis, industry developments, market growth drivers, emerging technologies, and future opportunities.

Conclusion

The global Plasma Fractionation Market is positioned for steady growth as healthcare systems respond to rising demand for plasma-derived therapies and improve access to specialized treatments. Growing awareness of rare and chronic diseases, healthcare infrastructure development, and investments in plasma collection are creating new opportunities across the industry.

At the same time, the market must address challenges related to plasma availability, manufacturing costs, regulatory requirements, and uneven global access. Strengthening plasma collection systems, improving fractionation technologies, and developing sustainable supply networks will remain important priorities.